Faricimab in neovascular age-related macular degeneration: updated week 48 efficacy, safety, and durability in the phase 3 TENAYA and LUCERNE trials

被引：0
|
作者：
London, Nikolas [1 ]
Guymer, Robyn H. [2 ,3 ]
Demetriades, Anna-Maria [4 ]
Ruiz, Carlos Quezada [4 ]
Silverman, David [5 ]
Ives, Jane [5 ]
Basu, Karen [6 ]
Lin, Hugh [4 ]
机构：
[1] Retina Consultants San Diego, San Diego, CA USA
[2] Ctr Eye Res Australia Ltd, Melbourne, Vic, Australia
[3] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] Roche Prod Ltd, Welwyn Garden City, Herts, England
[6] Roche Prod Ireland Ltd, Dublin, Ireland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2022年 / 63卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
3120
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Faricimab in neovascular age-related macular degeneration: Week 48 results from the phase 3 TENAYA and LUCERNE trials
    Guymer, Robyn H.
    Holz, Frank G.
    Lin, Hugh
    Basu, Karen
    Ruiz, Carlos Quezada
    Wong, Tien Y.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 49 (08): : 835 - 835
  • [2] Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials
    Khanani, Arshad
    Heier, Jeffrey
    Ruiz, Carlos
    Lin, Hugh
    Silverman, David
    Brittain, Christopher
    Ives, Jane
    Swaminathan, Balakumar
    Basu, Karen
    Wong, Tien
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [3] Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation
    Zou, Wenjun
    Jiang, Qin
    Wang, Yanling
    Wei, Wenbin
    Sun, Xiaodong
    Basu, Karen
    Chen, Qiuyu
    Kotecha, Aachal
    Li, Sijing
    Liu, Ruyuan
    Patel, Vaibhavi
    Chen, Youxin
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2025, 14 (01):
  • [4] Infographic: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE)
    Wijesingha, Naomi
    Sivaprasad, Sobha
    EYE, 2024, 38 (SUPPL 2) : 53 - 54
  • [5] Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials
    Kanji Takahashi
    Chui Ming Gemmy Cheung
    Tomohiro Iida
    Timothy Y. Y. Lai
    Masahito Ohji
    Yasuo Yanagi
    Mika Kawano
    Shino Ohsawa
    Tomoyuki Suzuki
    Aachal Kotecha
    Hugh Lin
    Vaibhavi Patel
    Balakumar Swaminathan
    Won Ki Lee
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261 : 3125 - 3137
  • [6] Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials
    Takahashi, Kanji
    Cheung, Chui Ming Gemmy
    Iida, Tomohiro
    Lai, Timothy Y. Y.
    Ohji, Masahito
    Yanagi, Yasuo
    Kawano, Mika
    Ohsawa, Shino
    Suzuki, Tomoyuki
    Kotecha, Aachal
    Lin, Hugh
    Patel, Vaibhavi
    Swaminathan, Balakumar
    Lee, Won Ki
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 261 (11) : 3125 - 3137
  • [7] Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
    Heier, Jeffrey S.
    Khanani, Arshad M.
    Ruiz, Carlos Quezada
    Basu, Karen
    Ferrone, Philip J.
    Brittain, Christopher
    Figueroa, Marta S.
    Lin, Hugh
    Holz, Frank G.
    Patel, Vaibhavi
    Lai, Timothy Y. Y.
    Silverman, David
    Regillo, Carl
    Swaminathan, Balakumar
    Viola, Francesco
    Cheung, Chui Ming Gemmy
    Wong, Tien Y.
    LANCET, 2022, 399 (10326): : 729 - 740
  • [8] Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
    Helene O. Larsen
    Jakob Grauslund
    Anna S. Vergmann
    Ophthalmology and Therapy, 2023, 12 : 2253 - 2264
  • [9] Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
    Larsen, Helene O.
    Grauslund, Jakob
    Vergmann, Anna S.
    OPHTHALMOLOGY AND THERAPY, 2023, 12 (05) : 2253 - 2264
  • [10] Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration
    Toto, Lisa
    Formenti, Federico
    Ruggeri, Maria Ludovica
    Quarta, Alberto
    Romano, Anna
    De Nicola, Chiara
    Baroni, Luca Belloni
    Porreca, Annamaria
    Di Nicola, Marta
    Mastropasqua, Rodolfo
    OPHTHALMIC RESEARCH, 2024, 67 (01) : 528 - 536
12345